当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Kalyani D
Cancer continues to be a global health challenge, affecting millions of people worldwide and posing significant morbidity and mortality rates. In this study, we aimed to investigate and analyze the oncological outcomes in cancer patients to gain a comprehensive understanding of prognosis and treatment effectiveness. We conducted a retrospective analysis of a large cohort of cancer patients from multiple medical centers, spanning diverse cancer types and stages. Data from electronic health records, medical imaging, pathology reports, and treatment regimens were collected for each patient. The analysis focused on several key aspects of oncological outcomes, including overall survival rates, disease-free survival, progression-free survival, and response rates to various therapeutic modalities. Additionally, we explored the impact of various prognostic factors, such as cancer type, stage at diagnosis, genetic mutations, and patient demographics. Our findings revealed significant variations in oncological outcomes across different cancer types and stages. We identified specific cancer types that showed promising treatment responses and those with poorer prognosis, enabling us to pinpoint areas requiring further research and therapeutic advancements. Moreover, we observed the influence of patient-specific factors on treatment outcomes, emphasizing the importance of personalized medicine in oncology. Furthermore, we analyzed the impact of different treatment approaches, including surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapies, on patient survival and quality of life. This analysis shed light on the effectiveness of specific treatments and highlighted potential areas for treatment optimization and enhancement. To better understand long-term outcomes, we also examined the role of survivorship care in cancer management, focusing on post-treatment complications, recurrence monitoring, and survivorshiprelated challenges.